Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) targeting lung mucosa cells — the epithelial lining of the alveoli and bronchioles that constitutes the functional respiratory surface for gas exchange. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Chonluten operates through the same epigenetic histone-DNA binding mechanism as the broader bioregulator series, specifically activating gene expression in pulmonary epithelial cells that declines with age, chronic environmental exposure, and inflammatory injury.

The lung's respiratory surface is a delicate epithelial structure with enormous functional consequences for the entire organism. Type I pneumocytes cover roughly 95% of the alveolar surface and are the primary sites of gas exchange — oxygen entry and CO2 elimination occur across their exceptionally thin membranes. Type II pneumocytes produce surfactant, the phospholipid-protein mixture that prevents alveolar collapse at end-expiration and plays crucial immune defense roles. Both cell types show age-related functional decline: reduced surfactant production, impaired barrier integrity, decreased proliferative capacity for self-renewal, and increased susceptibility to oxidative damage from inhaled oxidants.

Chonluten's tripeptide sequence activates transcription of genes critical to both pneumocyte populations: surfactant protein genes (SP-A, SP-B, SP-C, SP-D), tight junction proteins maintaining the alveolar barrier, antioxidant enzymes protecting epithelium from inhaled oxidative stress, and growth factors supporting type II pneumocyte proliferation for alveolar self-renewal. The Khavinson group's research demonstrates that Chonluten treatment in aging animals restores these gene expression profiles toward youthful patterns, with measurable improvements in lung histology (preserved alveolar architecture, better surfactant distribution, reduced inflammatory infiltration) and physiological parameters (improved gas exchange efficiency).

Clinically, Chonluten has been studied in aging populations with age-related pulmonary decline, patients with chronic non-infectious pulmonary disease, and individuals with occupational or environmental respiratory damage. Outcomes include improvements in spirometry, reduced frequency of respiratory infections (attributable to restored mucosal immune defense), and improvements in subjective breathing capacity. The peptide is particularly relevant for: aging individuals with progressive pulmonary function loss, those with environmental particulate exposure history, ex-smokers with residual alveolar damage, and patients recovering from pulmonary injury who need to rebuild alveolar tissue quality.

The distinction between Chonluten and Bronchogen is anatomical and functional: Bronchogen targets the bronchial epithelium (conducting airways), while Chonluten targets the alveolar and bronchiolar epithelium (gas exchange surface). Together they provide complete respiratory tract bioregulator coverage — bronchial wall restoration from Bronchogen, alveolar restoration from Chonluten. For comprehensive respiratory aging support, the combination addresses the full anatomical spectrum of age-related pulmonary decline.

Protocol is 1–2mg/day intranasally or by subcutaneous injection for 10 consecutive days, repeated 2–4 times per year. Intranasal administration is particularly relevant given that inhaled peptide can reach bronchiolar and distal airway epithelium directly — though systemic absorption following intranasal or SC administration also provides bioregulator activity at the alveolar level. Response is cumulative across course cycles.